Apheresis Market

SKU: DMMD2202 | Last Updated On: Nov 02 2022 | Available Formats

> Apheresis Market Expected to reach a high CAGR of 7.6% By 2029:

Apheresis Market is segmented By Product (Apheresis Devices, Plasma Separators, Plasma Component Separators, Immunoadsorption Columns, Plasma Perfusion Columns, Hemoperfusion Columns, Apheresis Disposables), By Technology (Centrifugation, Intermittent Flow, Continuous Flow, Membrane Separation), By Procedure (Plasmapheresis, Plateletpheresis, Erythrocytapheresis, Leukapheresis, Others), By Application (Neurological Disorders, Blood Disorders, Cardiovascular Disorders, Renal Disorders, Autoimmune Disorders, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2022-2029.

Apheresis Market

Apheresis market size was valued US$ 2.2 billion in 2021 and is estimated to reach US$ 4.1 billion by 2029, growing at a CAGR of 7.6% during the forecast period (2022-2029). Apheresis is a medical procedure that involves removing whole blood from a donor or patient and separating the blood into individual components so that one particular component can be removed. The remaining blood components then are re-introduced back into the bloodstream of the patient or donor. Hematologic diseases or disorders of the blood and blood-forming organs, afflict millions of people globally. In addition to blood cell cancers, hematologic diseases include rare genetic disorders, anemia, conditions related to HIV, sickle cell disease, and complications from chemotherapy or transfusions.

As per DataM Intelligence, Apheresis Market study analysis offers an in-depth outlook on the market containing quantitative and qualitative data. It gives an outlook and forecast of the global market based on market segmentation. It also provides global Apheresis Market size, and growth, along with the latest trends, opportunities, and forecast till 2029 for the global market with esteem to major countries such as the United States, Canada, Brazil, Germany, Italy, Spain, United Kingdom, Russia, European countries, United Arab Emirates, Saudi Arabia, South Africa, Japan, China, India, South Korea, Australia, and rest of the countries over the globe.

Among all regions, the North American region is expected to hold the largest share of the global market over the forecast period. Apheresis Market in the United States and Canada produces the utmost share. Whereas the European Apheresis Market is projected to continue its presence globally during the period of 2022- 2029.

Apheresis Market Scope

Metrics

Details

Market CAGR

9.60%

Segments Covered

By Technology, By Product, By Application, By Procedure, and By Region

Report Insights Covered

Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights.

Fastest Growing Region

Asia Pacific

Largest Market Share 

North America

To get a Free sample click here

Market Dynamics

Increase in hematological disorders and technological advancements are the major factors driving the global apheresis market.

Increase in hematological disorders and technological advancements are expected to drive market growth.

Leukemia is a blood cancer caused by a rise in the number of white blood cells in the body. Apheresis is one of the most common treatment methods for leukemia. Cytapheresis a type of apheresis procedure is the removal of specific cellular components from a patient or collection of cellular components from blood of a donor. Cytapheresis is known as leukapheresis where white blood cells (WBC) are separated from the blood.

Many chemotherapy drugs can temporarily impair blood cell production in the marrow and depress immune system functions. The defected blood cells can be replaced by blood transfusion from healthy donors which are collected by apheresis.

Many other hematological disorders are treated with apheresis technique such as sickle cell anemia. Red blood cell exchange is used to treat or sometimes prevent serious complications of sickle cell disease, such as stroke and acute chest syndrome. In red blood cell exchange, diseased or abnormal red blood cells are removed by apheresis and then replaced by donor red blood cells.

Red blood cells that are abnormal in shape, size or function, or that are too numerous, can deprive bodily tissues of oxygen or prevent oxygen from reaching the tissues. Lack of oxygen causes damage to cells and organs and may result in pain, anemia, stroke or kidney failure. Red blood cells apheresis helps treat these problems.

Red blood cells exchanges are also used to treat certain infections affecting red blood cells, such as malaria, or may be used in ABO-incompatible bone marrow transplants.

Risks associated with apheresis is expected to hamper the market growth.

Various risks are associated with the Apheresis procedure and the crucial one is blood contamination that is very common during the procedure. High cost of these procedures id also a big factor restraining the growth of market.

Industry Analysis

The Global Apheresis Market provides in-depth analysis of the market based on various industry factors such as Porter’s Five Forces, Regulatory & Reimbursement Analysis, Value Chain Analysis, Pricing Analysis, Comparative Scenario, PESTEL Analysis etc.

Segment Analysis

Plasmaphresis segment is expected to hold the largest market share in global apheresis market

Plasmapheresis is a process that filters the blood and removes harmful antibodies. It is a procedure done similarly to dialysis; however, it specifically removes antibodies from the plasma portion of the blood.

Antibodies against blood proteins can lead to rejection after a blood-type incompatible transplant. In severe cases, this could cause the kidney transplant to fail. Plasmapheresis before transplant removes antibodies against the donor blood-type from the recipient, so they can’t attack and damage the donated kidney.

Kidney transplant is the most desired and cost-effective modality of renal replacement therapy for patients with irreversible chronic kidney failure. According to National Institute of Health (NIH), chronic kidney disease, has a high global prevalence with a consistent estimated global prevalence of between 11 to 13% with the majority stage 3.

Increase in cases of chronic kidney diseases leads to increase in kidney transplants worldwide. Earlier a recipient can receive kidney only from the same blood group which led to delay in finding a proper donor. Delay in transplant was responsible for increased mortality.

Due to plasmapheresis procedure a recipient can receive a kidney from a donor of a different blood type. This procedure is currently being provided at a growing number of transplant centres. Patients with rare causes of kidney disease such as Wegner’s granulomatosis or Goodpasture syndrome also undergo plasmapheresis to treat their disease.

The American Society for Apheresis (ASFA) suggests plasmapheresis for critically ill patients with a variety of primary neurological disorders. The ASFA recommends plasmapheresis as a first line treatment in Acute Inflammatory Demyelinating Polyneuropathy (Guillain-Barre Syndrome), Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections and Sydenham’s Chorea (PANDAS), Multiple Sclerosis, and Myasthenia Gravis.

Plasmapheresis is also used as treatment in hyperviscosity syndromes, including myeloma. These conditions cause the blood to thicken, which can lead to organ damage or a stroke.

Geographical Analysis

North America region holds the largest market share in the global apheresis market

North America is dominating the market due to increased prevalence of chronic lifestyle related diseases in the region, increase in demand of blood components, technological advancements in the field and favourable government policies.

Chronic kidney disease causes more deaths than breast cancer or prostate cancer in the region. It is the under-recognized public health crisis. It affects an estimated 37 million people in the U.S. that is equivalent to 15% of the adult population or more than one in seven adults. The high prevalence of obesity, hypertension and diabetes are some of the reasons that are causing chronic kidney disease.

Kidney transplant is considered the best treatment option for people facing kidney failure because it can increase the chances of living a longer, healthier life.

Kidney rejection is a normal reaction of the body when a new kidney is placed in a person's body. The body sees the transplanted organ as a threat and tries to attack it. The immune system makes antibodies to try to kill the new organ, not realizing that the transplanted kidney is beneficial. These antibodies can be removed with apheresis hence decreasing the chance of kidney rejection.

Due to apheresis kidney can be donated by any blood group donor thus reducing the wait time for transplant.

Considering this, much more emphasis has been placed on improving treatment standards, which is likely to translate into higher demand for platelets and plasma for therapies and other treatment purposes. The increased use of plasma-derived biopharma drugs is driving demand for plasma-based therapies and related plasmapheresis devices.

Competitive Landscape

Haemonetics, Cerus Corporation and Terumo are among the companies that have launched technologically advanced plasmapheresis products such as to improve quality and compliance and increase productivity in plasma collection centers, Haemonetics offers the new NexSys PCS plasmapheresis system. Its open design empowers bidirectional connectivity to donor management systems, facilitating automated collection process programming and automated end-of-process documentation.

Global Apheresis Market – Key Companies to Watch

Fresenius SE & Co. KGaA:

Overview: Fresenius SE & Co. is a company of healthcare that is based in Germany and was founded in 1912. They manufacture products and services for various conditions such as Dialysis, in hospitals or inpatient medical care.

Product Portfolio: Prometheus system: It is a latest liver support systems that is used as a system that combines a classic dialysis procedure and adsorber treatment. In comparison to dialysis that is used in kidney failure, the liver failure also needs removal of toxins that is bound to the albumin

Key Developments: In Mar 2022, Fresenius SE & Co. & Interwell Health and Cricket Health merged and formed a new company that is going to operate as InterWell Health brand. They are going to focus on the products and services of initial phases of kidney disease.

The global apheresis market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.

 

Frequently Asked Questions

What is the Projected CAGR value of the Apheresis Market ?

Apheresis Market is expected to grow at a CAGR of 9.60% during the forecasting period 2022-2029.

Which region controlled the global market during 2022-2029?

North America region Controls the Apheresis Market  during 2022-2029.

Which is the fastest growing region in the Apheresis Market ?

Among all regions, Asia Pacific is the fastest growing market share during the forecast period.

Trending Topics

Japan Apheresis Market

Therapeutic Apheresis Market

Elastomer Infusion Pump Market

 

Did not find what you were looking for?Every 7 out of 10 customers request tailored reports. Get yours today!
We collate your requirements.
Our global research team is put into action.
We deliver, and make sure your endeavour is a success!

Buy This Report

20% Discount Applied*



Note*: For "Bundle/Bulk" Subscription of Reports,
please contact: [email protected]

Get your free sample proposal with a single click!

linkedinpinterest